Jillian Basinger Thompson

Patent Agent I


Jillian Thompson is a patent agent with Foley & Lardner LLP. Jillian is based in the firm’s San Diego office where she is a member of the Intellectual Property Industry Team.

Jillian has five years legal experience and nearly a decade of post-graduate experience as a medicinal chemist in the pharmaceutical industry. She prepares and prosecutes chemical patent applications, conducts prior art analyses to evaluate patentability and freedom-to-operate, and assists in the management of patent portfolios.

Prior to joining Foley, Jillian worked as a patent agent preparing chemical and biotechnology patent applications at a top-rated law firm. She also prosecuted U.S. and foreign patent applications, conducted prior art searches, and  assisted with patentability and freedom to operate (FTO) determinations. Jillian also served as an associate scientist and patent agent with Dart Neuroscience in San Diego. As a scientist, she designed and synthesized a novel series of CNS compounds for cognitive enhancement, analyzed co-crystal structures of lead compounds to design optimized analogs, and developed and completed multistep syntheses of lead compounds.

Earlier in her career, Jillian was a medicinal chemist at Ligand Pharmaceuticals, where she designed, synthesized and analyzed small molecules and completed multi-gram syntheses of lead compounds. As a graduate research associate at UC San Diego, Jillian designed and completed a convergent total synthesis of a precursor of the marine natural product oceanapiside, an α,ω-bis-aminohydroxylipid that exhibits antifungal activity.

Select Publications & Presentations

  • “Substituted cyclohexyl compounds as NOP inhibitors,” PCT Intl. Appl. (2019)
  • Co-author, “Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties,” J. Med. Chem. 2018, 61 (4), 6018-6033
  • “Substituted azetidinyl compounds as GlyT1 Inhibitors,” PCT Intl. Appl. (2016)
  • “Preparation of substituted 2, 4, 5, 6-tetrahydropyrrolo[3, 4-c]pyrazole and 4, 5, 6, 7-tetrahydro-2H-pyrazolo{4, 3-c}pyridine compounds as GlyT1 inhibitors,” PCT Intl. Appl. (2015)
  • “Preparation of substituted naphthyridine and quinolone compounds as MAO Inhibitors,” U.S. Pat. Appl. (2014)
  • “Preparation of substituted benzamide derivatives and analogs for use as hematopoietic growth factor receptor activators,”  US Pat. US 9,144,557 B2
  • “Preparation of small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors,” U.S. Pat. US 8,680,150 B2
  • “Towards the Synthesis of Oceanapiside: Asymmetric Epoxidation and Azide Opening of Long Chain Allylic Alcohols,” poster presentation at the American Society of Pharmacognosy Meeting, Corvallis, OR (July 2006)
  • Co-author, “Synthesis of a Lewis acid bearing cyclopentadienyl ligand and its tricarbonylmanganese(I) complex,” J. Organomet. Chem. (2005), 690 (9), 2159-2162
  • Co-author, “Effects of Steric Constraint on Chromium(III) Complexes of Tetraazamacrocycles. Chemistry and Excited-State Behavior of 1, 4-C2-Cyclam Complexes,” Inorganic Chemistry 2003, 42, 4885-4890


  • Former board director and fundraising committee chair, Girls on the Run San Diego
  • Member, American Chemical Society


  • University of California, San Diego (M.S.,2007)
    • Major: organic chemistry
  • San Jose State University (B.S., 2002)
    • Major: chemistry


  • United States Patent and Trademark Office